Anal Cancer - Pipeline Review, H1 2016


#703102

86pages

Global Markets Direct

$ 2000

In Stock

Anal Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Anal Cancer - Pipeline Review, H1 2016, provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anal Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Anal Cancer - Overview 8
Pipeline Products for Anal Cancer - Comparative Analysis 9
Anal Cancer - Therapeutics under Development by Companies 10
Anal Cancer - Therapeutics under Investigation by Universities/Institutes 12
Anal Cancer - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Anal Cancer - Products under Development by Companies 15
Anal Cancer - Products under Investigation by Universities/Institutes 16
Anal Cancer - Companies Involved in Therapeutics Development 17
Advaxis, Inc. 17
Amgen Inc. 18
Eli Lilly and Company 19
Genticel S.A. 20
ISA Pharmaceuticals B.V. 21
Novartis AG 22
Oryx GmbH & Co. KG 23
PDS Biotechnology Corporation 24
Sun Pharma Advanced Research Company Ltd. 25
Taiwan Liposome Company, Ltd. 26
Anal Cancer - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
axalimogene filolisbac - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GTL-001 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ISA-101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LN-145 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
paclitaxel albumin free - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
panitumumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PDR-001 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PDS-0101A - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
prexasertib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TLC-388 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Vicoryx - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Anal Cancer - Recent Pipeline Updates 57
Anal Cancer - Dormant Projects 77
Anal Cancer - Product Development Milestones 78
Featured News & Press Releases 78
Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac 78
Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer 78
Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold 78
Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer 79
Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer 80
Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience 80
Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV 81
Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV 81
Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy 82
Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables
Number of Products under Development for Anal Cancer, H1 2016 8
Number of Products under Development for Anal Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Anal Cancer - Pipeline by Advaxis, Inc., H1 2016 17
Anal Cancer - Pipeline by Amgen Inc., H1 2016 18
Anal Cancer - Pipeline by Eli Lilly and Company, H1 2016 19
Anal Cancer - Pipeline by Genticel S.A., H1 2016 20
Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 21
Anal Cancer - Pipeline by Novartis AG, H1 2016 22
Anal Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 23
Anal Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 24
Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 25
Anal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Anal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 57
Anal Cancer - Dormant Projects, H1 2016 77

List of Figures
Number of Products under Development for Anal Cancer, H1 2016 8
Number of Products under Development for Anal Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 13
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Mechanism of Actions, H1 2016 30
Number of Products by Stage and Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34